pulmonary-embolism
(3)
Inquis Medical, Inc.
Inquis Medical is a Silicon Valley medical device company founded in 2020 by serial medtech entrepreneurs Vahid and Mojgan Saadat. Its flagship AVENTUS Precision Thrombectomy System removes blood clots from patients with pulmonary embolism (PE) and deep vein thrombosis (DVT), using proprietary TrueClot tissue-sensing technology that gives physicians real-time feedback to distinguish blood, clot, and vessel wall while minimizing blood loss through autologous blood reinfusion. Backed by $115M in total funding including a $75M Series C in January 2026, the company is scaling nationwide commercial adoption after winning FDA 510(k) clearance for PE in 2025.
Penumbra, Inc.
Penumbra, Inc. is an Alameda, California medical device company that builds tools to pull life-threatening blood clots out of the body. Founded in 2004 by attorney-turned-CEO Adam Elsesser and neuro-interventional surgeon Dr. Arani Bose, it pioneered aspiration-based mechanical thrombectomy for acute ischemic stroke and expanded into peripheral, venous, and pulmonary clot removal with its Indigo and Lightning Flash systems. The company also runs an Immersive Healthcare arm using virtual reality (the REAL System) for rehabilitation and wellness. Public on the NYSE since 2015 under ticker PEN, Penumbra posted $1.4 billion in 2025 revenue and agreed in January 2026 to be acquired by Boston Scientific in a roughly $14.5 billion deal.
RapidAI
RapidAI builds FDA-cleared clinical AI software that reads CT, CTA, CT perfusion and MRI scans to flag stroke, aneurysms and pulmonary embolisms in minutes - giving hospital teams a faster path to treatment. The platform began life as the Stanford spin-out iSchemaView and now runs in more than 2,000 hospitals across 100+ countries.